drugset / Trial / NCT00542685

A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder

NCT00542685

Phase 3 Completed 551 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will evaluate the efficacy and safety of PD 0332334 for the treatment of generalized anxiety disorder.

Timeline

Start
2007-10
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject IMAGABALIN Other / unclassified 175 mg Oral
Subject IMAGABALIN Other / unclassified 225 mg Oral
Subject IMAGABALIN Other / unclassified 300 mg Oral